Dipexium Pharmaceuticals, Inc.

Dipexium Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments for serious bacterial infections. The firm aims to improve patient outcomes through its advanced therapeutic solutions. Dipexium Pharmaceuticals, Inc.

specializes in the research and development of new antibiotics for serious infections. The company underwent a significant business transition in December 2016 when it merged with PLx Pharma Inc. , enhancing its capabilities in the pharmaceutical sector. It is headquartered in New York, US, and is known for its dedication to addressing unmet medical needs in infectious disease.

The company was founded by individuals with extensive experience in the biopharmaceutical industry, although specific names are not disclosed. In 2016, it actively pursued funding to support its research endeavors. Dipexium Pharmaceuticals, Inc. develops therapeutic products aimed at combating serious bacterial infections.

Their lead product candidate focuses on treating infections caused by resistant bacterial strains, thereby addressing a critical gap in current antibiotic offerings. The company’s research initiatives target both healthcare providers and patients in need of effective treatment solutions, supporting a broad range of clinical applications across various healthcare settings. In the most recent financial year of 2021, Dipexium Pharmaceuticals, Inc. reported revenue of USD 8.

21 mn. The company faced challenges with an EBITDA of USD -40. 57 mn, highlighting the ongoing investment in research and development to advance its product pipeline. Dipexium Pharmaceuticals, Inc.

is strategically positioned to introduce new antibiotic treatments in the near future, although specific product release dates are not disclosed. The company aims to expand its market presence, focusing on jurisdictions with high unmet medical needs, specifically targeting North America and Europe for its growth initiatives. Recent funding from the merger with PLx Pharma Inc. in December 2016 will be utilized to facilitate the development and commercialization of its innovative therapies, reinforcing the company’s commitment to improving healthcare outcomes.